Alexion Pharmaceuticals Inc.
http://www.alexion.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alexion Pharmaceuticals Inc.
Biogen Seeking A Path Forward After Phase III Tofersen Study Fails In ALS
The drug showed favorable but not significant trends across secondary endpoints, and greater efficacy in slower-progressing patients and those treated earlier in the disease, in a small subpopulation.
Health And Wellness Industry: IFF CEO Leaving, Abbott/Real Madrid Score Partnership, More
International Flavors & Fragrances looks for CEO to replace Andreas Fibig; Ultrahuman Healthcare appoints private equity expert as business chief; prebiotics developer Clasado taps nutritional scientist; Abbott kicks off nutritional partnership with Real Madrid; and CRN adjusts membership fees.
Bio-Thera Strengthens Ties With Pharmapark By Adding Ustekinumab
Deal-happy Bio-Thera Solutions has signed another license and supply agreement, agreeing to out-license its BAT2206 biosimilar ustekinumab candidate in Russia and other CIS countries to local player Pharmapark.
US Q3 Consumer Health Earnings Preview: Helm Changes, Supply Challenges, Separation Plan
July-September results for sales of OTC drugs, supplements and personal care products will come with CEO leaving J&J and P&G, a new leader for Perrigo Americas, Bausch Health likely offering Bausch + Lomb separation details and a cloud of rising costs related to supplies.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Alexion Pharma K.K. (formerly Legend K.K. or Legend Pharma Co., Ltd.) (Japan)
- AstraZeneca PLC
- Enobia Pharma Corp.
- Portola Pharmaceuticals, Inc. (PTLA)
- Synageva BioPharma Corp.
- Syntimmune, Inc.
- Taligen Therapeutics, Inc.
- Wilson Therapeutics AB